PARD (Poniard Pharmaceuticals) Total Liabilities: $4.62 Mil (As of Sep. 2011)


What is Poniard Pharmaceuticals Total Liabilities?

Poniard Pharmaceuticals PARD Total Liabilities is $4.62 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2011 was $4.62 Mil.

Poniard Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2011 ($2.88 Mil) to Jun. 2011 ($3.71 Mil) and increased from Jun. 2011 ($3.71 Mil) to Sep. 2011 ($4.62 Mil).

Poniard Pharmaceuticals's annual Total Liabilities declined from Dec. 2008 ($36.59 Mil) to Dec. 2009 ($28.80 Mil) and declined from Dec. 2009 ($28.80 Mil) to Dec. 2010 ($3.19 Mil).

Poniard Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Liabilities Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.18 16.04 36.59 28.80 3.19

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.01 3.19 2.88 3.71 4.62

Poniard Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Poniard Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2010 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.616+(1.574+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.19

Total Liabilities=Total Assets (A: Dec. 2010 )-Total Equity (A: Dec. 2010 )
=11.643-8.453
=3.19

Poniard Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2011 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.979+(1.64+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.62

Total Liabilities=Total Assets (Q: Sep. 2011 )-Total Equity (Q: Sep. 2011 )
=7.736-3.117
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $4.62 Mil mean?
Poniard Pharmaceuticals (PARD) has a Total Liabilities of $4.62 Mil as of Sep. 2011. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Total Liabilities too high?
Poniard Pharmaceuticals' current Total Liabilities is $4.62 Mil.
How does Poniard Pharmaceuticals' Total Liabilities compare to OBMP and NSPX?
Poniard Pharmaceuticals' Total Liabilities of $4.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Total Liabilities is $4.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Total Liabilities of $4.62 Mil. The current Total Liabilities is $4.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Total Liabilities is $4.62 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.